

Atomoxetine Treatment of ADHD in Children With Com

Journal of Attention Disorders

11, 470-481

DOI: [10.1177/1087054707306109](https://doi.org/10.1177/1087054707306109)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Atomoxetine treatment of ADHD in Tourette Syndrome: Reduction in motor cortex inhibition correlates with clinical improvement. <i>Clinical Neurophysiology</i> , 2007, 118, 1835-1841.	0.7	24
2	Issues in the Management of Patients with Complex ADHD Symptoms. <i>Journal of Pediatrics</i> , 2009, 154, I-S43.	0.9	1
3	Safety and Efficacy Limitations of ADHD Pharmacotherapy. <i>Journal of Pediatrics</i> , 2009, 154, I-S43.	0.9	3
4	ADHD and the Prefrontal Cortex. <i>Journal of Pediatrics</i> , 2009, 154, I-S43.	0.9	105
5	Advances in ADHD Therapy: Investigation of Alpha-2a Agonists. <i>Journal of Pediatrics</i> , 2009, 154, I-S43.	0.9	0
7	Attention-Deficit-Hyperactivity Disorder: An Update. <i>Pharmacotherapy</i> , 2009, 29, 656-679.	1.2	226
13	CME Section. <i>Journal of Pediatrics</i> , 2009, 154, I-S43.	0.9	0
14	Update on atomoxetine in the treatment of attention-deficit/hyperactivity disorder. <i>Expert Opinion on Pharmacotherapy</i> , 2009, 10, 669-676.	0.9	45
15	Toward a New Understanding of Attention-Deficit Hyperactivity Disorder. <i>CNS Drugs</i> , 2009, 23, 5-8.	2.7	3
16	Efficacy and Safety Limitations of Attention-Deficit Hyperactivity Disorder Pharmacotherapy in Children and Adults. <i>CNS Drugs</i> , 2009, 23, 21-31.	2.7	125
17	Use of Atomoxetine in Patients with Attention-Deficit Hyperactivity Disorder and Co-Morbid Conditions. <i>CNS Drugs</i> , 2009, 23, 739-753.	2.7	20
18	InforMatrix for attention deficit hyperactivity disorder. <i>Expert Opinion on Pharmacotherapy</i> , 2009, 10, 755-772.	0.9	1
19	Tourette Syndrome. <i>Neurologic Clinics</i> , 2009, 27, 737-755.	0.8	18
20	Meta-Analysis: Treatment of Attention-Deficit/Hyperactivity Disorder in Children With Comorbid Tic Disorders. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2009, 48, 884-893.	0.3	232
21	Drug treatments for attention-deficit hyperactivity disorder in young people. <i>Advances in Psychiatric Treatment</i> , 2009, 15, 162-171.	0.6	7
22	Pharmacotherapeutics of Tourette Syndrome and Stereotypies in Autism. <i>Seminars in Pediatric Neurology</i> , 2010, 17, 254-260.	1.0	27
24	Atomoxetine Versus Stimulants in the Community Treatment of Children With ADHD. <i>Journal of Attention Disorders</i> , 2010, 13, 391-400.	1.5	13
25	Update on tic disorders and Tourette syndrome. <i>Paediatrics and Child Health (United Kingdom)</i> , 2010, 20, 411-415.	0.2	3

#	ARTICLE	IF	CITATIONS
26	Attention-Deficit Hyperactivity Disorder. <i>Drugs</i> , 2010, 70, 15-40.	4.9	53
27	Tic Suppression: The Medical Model. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2010, 20, 263-276.	0.7	17
28	Core ADHD Symptom Improvement With Atomoxetine Versus Methylphenidate. <i>Journal of Attention Disorders</i> , 2011, 15, 674-683.	1.5	59
31	Pharmacological treatment for Attention Deficit Hyperactivity Disorder (ADHD) in children with comorbid tic disorders. <i>The Cochrane Library</i> , 2011, , CD007990.	1.5	68
32	To stop or not to stop? How long should medication treatment of attention-deficit hyperactivity disorder be extended?. <i>European Neuropsychopharmacology</i> , 2011, 21, 584-599.	0.3	93
33	The occurrence of adverse drug reactions reported for attention deficit hyperactivity disorder (ADHD) medications in the pediatric population: a qualitative review of empirical studies. <i>Neuropsychiatric Disease and Treatment</i> , 2011, 7, 729.	1.0	41
35	European guidelines on managing adverse effects of medication for ADHD. <i>European Child and Adolescent Psychiatry</i> , 2011, 20, 17-37.	2.8	302
36	European clinical guidelines for Tourette syndrome and other tic disorders. Part II: pharmacological treatment. <i>European Child and Adolescent Psychiatry</i> , 2011, 20, 173-196.	2.8	374
37	Update on Attention-Deficit/Hyperactivity Disorder and Tic Disorders: A Review of the Current Literature. <i>Current Psychiatry Reports</i> , 2011, 13, 351-356.	2.1	36
38	Tics and Tourette syndrome. , 2011, , 350-379.		4
39	Neurodevelopmental Disabilities. , 2011, , .		18
40	Atomoksetin KullanÄ±mÄ±na BaÄŸlıÄ± Motor Tikler: Olgu Sunumu. <i>Journal of Microbiology and Biotechnology</i> , 2011, 21, 364-367.	0.9	2
41	Attention Deficit Hyperactivity Disorder Through The Life Cycle. <i>Focus (American Psychiatric)</i> Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 262 0,4 1	0.4	1
42	Aripiprazole in Children with Tourette's Disorder and Co-morbid Attention-Deficit/Hyperactivity Disorder: A 12-Week, Open-Label, Preliminary Study. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2012, 22, 120-125.	0.7	28
43	Off-label use of atomoxetine in adults: is it safe?. <i>Mental Illness</i> , 2012, 4, 96-101.	0.8	9
44	In Memoriam. <i>Journal of Child Neurology</i> , 2012, 27, 1355-1359.	0.7	0
46	Cochrane Review: Pharmacological treatment for Attention Deficit Hyperactivity Disorder (ADHD) in children with comorbid tic disorders. <i>Evidence-Based Child Health: A Cochrane Review Journal</i> , 2012, 7, 1196-1230.	2.0	0
47	Children and adolescents with Touretteâ€™s disorder in the USA versus Argentina: behavioral differences may reflect cultural factors. <i>European Child and Adolescent Psychiatry</i> , 2013, 22, 701-707.	2.8	4

#	ARTICLE	IF	CITATIONS
48	Pharmacological treatment of tic disorders and Tourette Syndrome. <i>Neuropharmacology</i> , 2013, 68, 143-149.	2.0	118
49	Tourette Syndrome and comorbid ADHD: Current pharmacological treatment options. <i>European Journal of Paediatric Neurology</i> , 2013, 17, 421-428.	0.7	64
50	Practice Parameter for the Assessment and Treatment of Children and Adolescents With Tic Disorders. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2013, 52, 1341-1359.	0.3	196
51	Atomoxetine for Treating ADHD Symptoms in Autism. <i>Journal of Attention Disorders</i> , 2013, 17, 635-640.	1.5	35
52	Emerging Treatment Strategies in Tourette Syndrome. <i>International Review of Neurobiology</i> , 2013, 112, 445-480.	0.9	34
53	Clinical Pharmacology of Comorbid Attention Deficit Hyperactivity Disorder in Tourette Syndrome. <i>International Review of Neurobiology</i> , 2013, 112, 415-444.	0.9	23
54	Pharmacotherapeutic Challenges in the Management of Attention-Deficit/Hyperactivity Disorder and Chronic Tics in a School Aged Child. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2013, 23, 628-631.	0.7	3
55	Pharmacological Treatment of Attention Deficit Hyperactivity Disorder in Children and Adolescents: Clinical Strategies. <i>Journal of Central Nervous System Disease</i> , 2013, 5, JCNSD.S6691.	0.7	37
57	Predictors of Polypharmacy and Off-Label Prescribing of Psychotropic Medications. <i>Journal of Psychiatric Practice</i> , 2014, 20, 438-447.	0.3	21
58	Tourette Syndrome. <i>Paediatrics and Child Health (United Kingdom)</i> , 2014, 24, 447-451.	0.2	7
59	Updates in Medical and Surgical Therapies for Tourette Syndrome. <i>Current Neurology and Neuroscience Reports</i> , 2014, 14, 458.	2.0	26
60	Complexities for Assessment and Treatment of Co-Occurring ADHD and Tics. <i>Current Developmental Disorders Reports</i> , 2015, 2, 293-299.	0.9	22
61	Non-stimulant treatment of ADHD. , 0, , 259-275.		1
62	ADHD and tic disorders. , 0, , 343-352.		2
63	A critical appraisal of atomoxetine in the management of ADHD. <i>Therapeutics and Clinical Risk Management</i> , 2016, 12, 27.	0.9	43
64	The Efficacy of Atomoxetine for the Treatment of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Comprehensive Review of Over a Decade of Clinical Research. <i>CNS Drugs</i> , 2015, 29, 131-151.	2.7	37
65	Advances in Tourette Syndrome. <i>Pediatric Clinics of North America</i> , 2015, 62, 687-701.	0.9	35
66	Neuropsychiatric Symptoms of Movement Disorders. <i>Neuropsychiatric Symptoms of Neurological Disease</i> , 2015, , .	0.3	0

#	ARTICLE	IF	CITATIONS
67	Efficacy of atomoxetine in the treatment of attention-deficit hyperactivity disorder in patients with common comorbidities in children, adolescents and adults: a review. <i>Therapeutic Advances in Psychopharmacology</i> , 2016, 6, 317-334.	1.2	33
68	The Safety of Atomoxetine for the Treatment of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Comprehensive Review of Over a Decade of Research. <i>CNS Drugs</i> , 2016, 30, 603-628.	2.7	73
69	Sex Differences in the Effect of Atomoxetine on the QT Interval in Adult Patients With Attention-Deficit Hyperactivity Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2017, 37, 27-31.	0.7	5
70	A review of the efficacy of atomoxetine in the treatment of attention-deficit hyperactivity disorder in children and adult patients with common comorbidities. <i>Neuropsychiatric Disease and Treatment</i> , 2017, Volume 13, 357-371.	1.0	35
71	Touretteâ€™s syndrome and its borderland. <i>Practical Neurology</i> , 2018, 18, 262-270.	0.5	37
72	Psychiatric Treatment and Management of Psychiatric Comorbidities of Movement Disorders. <i>Seminars in Pediatric Neurology</i> , 2018, 25, 123-135.	1.0	1
73	Pharmacological treatment for attention deficit hyperactivity disorder (ADHD) in children with comorbid tic disorders. <i>The Cochrane Library</i> , 2018, 2018, CD007990.	1.5	52
74	Tourette disorder and other tic disorders. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2019, 165, 123-153.	1.0	38
75	Changes in serum miRNA-let-7 level in children with attention deficit hyperactivity disorder treated by repetitive transcranial magnetic stimulation or atomoxetine: An exploratory trial. <i>Psychiatry Research</i> , 2019, 274, 189-194.	1.7	21
76	Treatment of psychiatric disturbances in common hyperkinetic movement disorders. <i>Expert Review of Neurotherapeutics</i> , 2019, 19, 55-65.	1.4	7
77	Tics and Tourette syndrome. , 2021, , 418-450.e15.		0
78	Evidence-based pharmacological treatment options for ADHD in children and adolescents. , 2022, 230, 107940.		68
79	Frontal Lobe Disorders in Pediatric Neuropsychology: Attention-Deficit Hyperactivity Disorder and Tourette Disorder. , 2010, , 251-273.		2
81	Tic Symptoms Induced by Atomoxetine in Treatment of ADHD: A Case Report and Literature Review. <i>Journal of Developmental and Behavioral Pediatrics</i> , 2017, 38, 151-154.	0.6	8
82	Pharmacotherapies to tics: a systematic review. <i>Oncotarget</i> , 2018, 9, 28240-28266.	0.8	4
83	Clinical effectiveness and patient perspectives of different treatment strategies for tics in children and adolescents with Tourette syndrome: a systematic review and qualitative analysis. <i>Health Technology Assessment</i> , 2016, 20, 1-450.	1.3	110
84	Optimizing Clinical Outcomes Across Domains of Life in Adolescents and Adults With ADHD. <i>Journal of Clinical Psychiatry</i> , 2011, 72, 1008-1014.	1.1	8
85	Methylphenidate-induced Exacerbation of Chorea in a Child Resolved with Switching to Atomoxetine. <i>Clinical Psychopharmacology and Neuroscience</i> , 2020, 18, 327-330.	0.9	4

#	ARTICLE	IF	CITATIONS
86	Psychische Störungen im Kindes- und Jugendalter. , 2009, , 373-412.		0
87	Tic Disorders. , 2011, , 213-226.		0
90	Psychische Störungen und umschriebene Entwicklungsstörungen im Kindes- und Jugendalter. , 2014, , 461-506.		0
91	Tics. Neuropsychiatric Symptoms of Neurological Disease, 2015, , 223-259.	0.3	0
94	Effectiveness and safety of methylphenidate and atomoxetine for attention deficit hyperactivity disorder: a systematic review. Translational Pediatrics, 2012, 1, 47-53.	0.5	0
95	The Mechanism, Clinical Efficacy, Safety, and Dosage Regimen of Atomoxetine for ADHD Therapy in Children: A Narrative Review. Frontiers in Psychiatry, 2021, 12, 780921.	1.3	23
97	Pharmacologic Treatment of Comorbid Attention-Deficit/Hyperactivity Disorder and Tourette and Tic Disorders. Child and Adolescent Psychiatric Clinics of North America, 2022, , .	1.0	1
98	Treatment of Psychiatric Comorbidities in Tourette Syndrome. , 2022, , 447-476.		0
99	Clinical Rating Instruments in Tourette Syndrome. , 2022, , 343-365.		0
101	Pharmacological treatment of Tourette's syndrome: from the past to the future. Neurological Sciences, 2024, 45, 941-962.	0.9	0
102	Psychostimulanzien und andere Arzneistoffe, die zur Behandlung der Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung (ADHS) angewendet werden. , 2023, , 375-441.		0